Albuterol ( DrugBank: Albuterol )

7 diseases

12. 先天性筋無力症候群

臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 13

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01203592 (ClinicalTrials.gov)	September 2010	15/9/2010	Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes	Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes	Congenital Myasthenic Syndrome	Drug: Albuterol	Mayo Clinic	NULL	Completed	2 Years	N/A	Both	21	Phase 1	United States

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00039988 (ClinicalTrials.gov)	November 2001	18/6/2002	Treatment of Multiple Sclerosis With Copaxone and Albuterol	Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol	Autoimmune Diseases;Multiple Sclerosis	Drug: Glatiramer acetate;Drug: Albuterol;Drug: Albuterol placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Completed	18 Years	55 Years	Both	40	N/A	United States

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03270332 (ClinicalTrials.gov)	October 5, 2017	30/8/2017	Effect of Inhaled Albuterol in Pulmonary Hypertension	Effect of Inhaled Albuterol on Pulmonary Hemodynamics in Patients With Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study	Pulmonary Hypertension	Drug: Albuterol;Drug: Placebo	University of Miami	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States
2	NCT02108743 (ClinicalTrials.gov)	June 2014	7/4/2014	Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension	Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension	Idiopathic Pulmonary Arterial Hypertension.	Drug: Albuterol.;Drug: Normal saline placebo	American Medical Association Foundation	NULL	Withdrawn	18 Years	75 Years	Both	0	Phase 2	United States

臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01799538 (ClinicalTrials.gov)	June 10, 2013	23/2/2013	Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis	Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis	Lymphangioleiomyomatosis	Drug: albuterol inhaler;Drug: albuterol nebulizer;Procedure: PFT	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Recruiting	18 Years	N/A	Female	100	Phase 1/Phase 2	United States

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004685 (ClinicalTrials.gov)	January 1998	24/2/2000	Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy		Muscular Dystrophy, Facioscapulohumeral	Drug: albuterol	Ohio State University	NULL	Completed	18 Years	80 Years	Both	90	N/A	NULL

臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01885936 (ClinicalTrials.gov)	June 2013	21/6/2013	Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease	A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy	Pompe Disease	Drug: Albuterol;Drug: Placebo	Duke University	NULL	Completed	18 Years	N/A	All	16	Phase 1/Phase 2	United States
2	NCT01859624 (ClinicalTrials.gov)	June 2012	8/5/2013	Albuterol in Individuals With Late Onset Pompe Disease (LOPD)	A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy	Pompe Disease	Drug: Albuterol	Duke University	NULL	Completed	18 Years	N/A	All	8	Phase 1	United States

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01880723 (ClinicalTrials.gov)	May 2009	15/6/2013	Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis	Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels	Cystic Fibrosis;Healthy	Drug: Albuterol;Drug: Placebo saline	University of Arizona	National Heart, Lung, and Blood Institute (NHLBI)	Completed	15 Years	55 Years	All	32	N/A	United States
2	NCT00005110 (ClinicalTrials.gov)	April 2000	13/4/2000	A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis		Cystic Fibrosis	Drug: Salmeterol;Drug: Albuterol	National Center for Research Resources (NCRR)	NULL	Suspended	5 Years	45 Years	Both		N/A	United States